Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy...
SchizophreniaSchizoaffective DisorderThis study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
Smoking Relapse Prevention in Schizophrenia
SchizophreniaSchizoaffective Disorder1 moreThis study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia
SchizophreniaSchizoaffective DisorderThis proposal seeks to evaluate a pilot smoking cessation treatment program that will combine nicotine replacement therapy with or without bupropion sustained-release (SR) with cognitive behavioral therapy for smoking cessation in patients with major mental illness.
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
SchizophreniasPsychoses2 moreThe etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. In addition to dopamine system hyperactivity, hypofunction of N-methyl-D-aspartate (NMDA) receptor plays a role in the pathophysiology of schizophrenia. Consequently, enhancing NMDA receptor neurotransmission has been considered as a novel treatment approach. To date, there have been several trials on NMDA enhancers reported. For example, sarcosine (N-methylglycine, a glycine transporter I inhibitor) showed therapeutic effects not only in chronically stable patients but also in acutely exacerbated ones when added-on to antipsychotics. In addition, sarcosine yields excellent safety profiles, in comparison to current antipsychotics. It remains unclear whether NMDA enhancers, such as sarcosine, can serve as monotherapy for schizophrenia. The aims of this project are to examine the efficacy and safety of sarcosine monotherapy for acutely-ill schizophrenic patients, and to compare the effects of 2 grams/day, effective dose, with 1 gram/day, ineffective lower dose.
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
SchizophreniaSchizoaffective DisordersThe purpose of the study is to assess and compare the side effect profile, safety, tolerability and efficacy of schizophrenic or schizoaffective subjects non- or partially- responsive to 800 mg/day of quetiapine treated with either 800 mg/day or more than 800 mg/day of quetiapine during 8 weeks.
Augmenting Clozapine With Sertindole - SERCLOZ
SchizophreniaThe purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission...
SchizophreniaThe purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) during the study observation period of 36 months.
Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia...
SchizophreniaThis study evaluated the effectiveness of Cognitive Behavioral Social Skills Training versus goal-focused supportive contact in improving social functioning in people with schizophrenia.
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia...
SchizophreniaExtrapyramidal SyndromeWe initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications. We compare the incidence of using anticholinergic drugs in schizophrenic patients of Han ethnics with neuroleptic-induced acute dystonia or parkinsonism to test the hypothesis that these two medications have different EPS incidence in EPS intolerant population.
Amisulpride in Schizophrenic Patients
SchizophreniaPrimary purpose: To find out how effective is long term treatment with amisulpride on the positive and negative symptoms in schizophrenic patients To find out how safe is long term treatment with amisulpride in schizophrenic patients Secondary purpose: To find out how effective is long term treatment with amisulpride on the quality of life in schizophrenic patients To find out how effective is long term treatment with amisulpride on the cognitive function in schizophrenic patients